North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
about
Brain tumorsRadioresistance of Brain TumorsTherapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsImproving the efficacy of chemoradiation with targeted agentsA phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KRTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistanceThe mTOR signaling pathway as a treatment target for intracranial neoplasmsThe challenges and the promise of molecular targeted therapy in malignant gliomas.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiformeCombining molecular targeted agents with radiation therapy for malignant gliomasCurrent clinical development of PI3K pathway inhibitors in glioblastoma.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.Targeted therapy in gliomas.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Inhibiting 4EBP1 in glioblastoma.Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.Investigational new drugs for brain cancer.Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I.Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma.Radiation-induced esophagitis exacerbated by everolimus.Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences.A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.
P2860
Q24605136-B2ED67AD-880D-40CA-9F4B-D7098157FFB4Q26752579-6A78713F-B137-4282-B0A6-9C9B0D30D817Q26764947-003871D2-C312-43B2-895F-E3FDF20D0BF3Q26829873-46C7EDCC-099B-4B3B-BCDD-2987DA1147E2Q26850193-94FED6B0-25F1-409D-9ED4-8D772C2C4EEFQ30301096-E32C0301-A3D6-4795-9983-09A41B9FA131Q33408116-DF09D0E0-AF9D-4F31-AECF-3C46763EF883Q33423176-66CE5DFC-2BBC-4D5D-8087-A0A88A35754AQ33820264-E6DB1A49-6130-4F0C-BE2C-290B1721E23BQ34886859-2A06F6B4-6A4E-4AF2-B094-75369E9DD1BDQ35214534-9444A36D-49F2-44A4-AFFC-98BBA560D547Q36086507-94DA41C1-F242-44B2-9939-DF106911F69EQ36658345-8BCB99E2-FCCC-4275-B8FB-E359321B9AF8Q37099594-21B02BF1-1F0F-451C-83E5-8E0160B7A537Q38012438-0CB09F65-941E-4A19-BD25-B1A3C7F191AEQ38065993-CE36B16A-8C90-4291-8761-F9FEB23A6205Q38102636-BFB9C27C-924E-4A7C-96FB-9191520A2221Q38183283-72E3AD78-DA70-4162-BDA9-83B363A442ADQ38186656-ABC8A906-F231-40F9-B5C1-7C7071CCF143Q38233105-23F00ED5-72DF-4253-9CF0-58EE1F742952Q38659417-1C2DE297-074B-407F-AD26-ADB5D07122EEQ38742022-AB069B4D-E6E4-4F9E-AEA8-ACE0882DCC11Q38832510-03EA85F7-AF9B-4540-B26A-20907C3D78F8Q39009280-B9437541-E97E-4D4D-82AB-002FC0860E82Q39748979-0469EA04-20B1-4AAD-A7CD-77E771D9FC14Q41142096-F0CFB12D-E6EC-4C34-80DF-3BCD86E6C3ABQ41889900-F2D7B3E0-2729-48A7-A277-6F1E5B95F8ECQ48009516-CEAC2B90-4789-48BF-B31E-EE955B04D5C5Q48158155-AA72235B-265C-40EF-A3BC-94E096ECC4CAQ50068283-E126C4F0-4F5B-4AE1-AC48-267555A0041BQ54286593-33842B06-B582-4A43-B692-26E8392ABAD8Q54289093-40255665-6B8C-4ECB-8534-E18077820DB0
P2860
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@ast
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@en
North Central Cancer Treatment Group Phase I trial N057K of everolimus
@nl
type
label
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@ast
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@en
North Central Cancer Treatment Group Phase I trial N057K of everolimus
@nl
prefLabel
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@ast
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@en
North Central Cancer Treatment Group Phase I trial N057K of everolimus
@nl
P2093
P2860
P1476
North Central Cancer Treatment ...... nosed glioblastoma multiforme.
@en
P2093
Caterina Giannini
Jan C Buckner
Jann N Sarkaria
Joon H Uhm
Kurt A Jaeckle
Patrick J Peller
Paul D Brown
Steven McGraw
Wenting Wu
P2860
P304
P356
10.1016/J.IJROBP.2010.05.064
P407
P577
2010-09-23T00:00:00Z